Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy

Ruben Y. G. Tijssen, Rene J. van der Schaaf, Robin P. Kraak, Maarten A. Vink, Sjoerd H. Hofma, E. Karin Arkenbout, Auke P. J. D. Weevers, Laura S. M. Kerkmeijer, Yoshinobu Onuma, Patrick W. Serruys, Marcel A. M. Beijk, Karel T. Koch, Jan Baan, M. Marije Vis, Jan J. Piek, Jan G. P. Tijssen, Jose P. S. Henriques, Robbert J. de Winter, Joanna J. Wykrzykowska

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Patients with acute coronary syndrome (ACS) might represent a specific subgroup, in which bioresorbable scaffold implantation in percutaneous coronary intervention (PCI), might lead to better outcomes when compared to conventional treatment with metallic drug eluting stents. In this prespecified subgroup analysis of the Amsterdam Investigator-Initiated Absorb Strategy All-Comers (AIDA) trial, we evaluated the clinical outcomes of Absorb bioresorbable vascular scaffold (BVS) versus Xience everolimus eluting stent (EES) treated patients presenting either with or without ACS. Methods and results: We classified AIDA patients on the basis of clinical presentation of ACS or of no-ACS. The rate of the 2-year primary endpoint of target vessel failure (TVF) was similar after treatment with Absorb BVS or Xience EES in ACS patients (10.2% versus 9.0% respectively; P = 0.49) and in no-ACS patients (11.7% versus 10.7%, respectively; P = 0.67) Definite or probable device thrombosis occurred more frequently with Absorb BVS compared to Xience EES in ACS patients (4.3% versus 1.7%, respectively, P = 0.03) as well as in no-ACS patients (2.4% versus 0.2%, respectively; P = 0.002). There were no statistically significant interactions between clinical presentation and randomized device modality for TVF (P = 0.80) and for the endpoint of definite or probable device thrombosis (P = 0.17). Conclusion: In the AIDA trial, the 2-year outcomes of PCI with Absorb BVS versus Xience EES were consistent in ACS and no-ACS patients: similar rates for TVF and consistently higher rates of definite or probable stent thrombosis under Absorb BVS versus Xience EES. There were no statistically significant interactions between clinical presentation and randomized device modality.
Original languageEnglish
JournalCatheterization and Cardiovascular Interventions
DOIs
Publication statusPublished - 2019

Cite this

Tijssen, Ruben Y. G. ; van der Schaaf, Rene J. ; Kraak, Robin P. ; Vink, Maarten A. ; Hofma, Sjoerd H. ; Arkenbout, E. Karin ; Weevers, Auke P. J. D. ; Kerkmeijer, Laura S. M. ; Onuma, Yoshinobu ; Serruys, Patrick W. ; Beijk, Marcel A. M. ; Koch, Karel T. ; Baan, Jan ; Vis, M. Marije ; Piek, Jan J. ; Tijssen, Jan G. P. ; Henriques, Jose P. S. ; de Winter, Robbert J. ; Wykrzykowska, Joanna J. / Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. In: Catheterization and Cardiovascular Interventions. 2019.
@article{408913d6efd34cc097be5a31d05290c1,
title = "Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy",
abstract = "Background: Patients with acute coronary syndrome (ACS) might represent a specific subgroup, in which bioresorbable scaffold implantation in percutaneous coronary intervention (PCI), might lead to better outcomes when compared to conventional treatment with metallic drug eluting stents. In this prespecified subgroup analysis of the Amsterdam Investigator-Initiated Absorb Strategy All-Comers (AIDA) trial, we evaluated the clinical outcomes of Absorb bioresorbable vascular scaffold (BVS) versus Xience everolimus eluting stent (EES) treated patients presenting either with or without ACS. Methods and results: We classified AIDA patients on the basis of clinical presentation of ACS or of no-ACS. The rate of the 2-year primary endpoint of target vessel failure (TVF) was similar after treatment with Absorb BVS or Xience EES in ACS patients (10.2{\%} versus 9.0{\%} respectively; P = 0.49) and in no-ACS patients (11.7{\%} versus 10.7{\%}, respectively; P = 0.67) Definite or probable device thrombosis occurred more frequently with Absorb BVS compared to Xience EES in ACS patients (4.3{\%} versus 1.7{\%}, respectively, P = 0.03) as well as in no-ACS patients (2.4{\%} versus 0.2{\%}, respectively; P = 0.002). There were no statistically significant interactions between clinical presentation and randomized device modality for TVF (P = 0.80) and for the endpoint of definite or probable device thrombosis (P = 0.17). Conclusion: In the AIDA trial, the 2-year outcomes of PCI with Absorb BVS versus Xience EES were consistent in ACS and no-ACS patients: similar rates for TVF and consistently higher rates of definite or probable stent thrombosis under Absorb BVS versus Xience EES. There were no statistically significant interactions between clinical presentation and randomized device modality.",
author = "Tijssen, {Ruben Y. G.} and {van der Schaaf}, {Rene J.} and Kraak, {Robin P.} and Vink, {Maarten A.} and Hofma, {Sjoerd H.} and Arkenbout, {E. Karin} and Weevers, {Auke P. J. D.} and Kerkmeijer, {Laura S. M.} and Yoshinobu Onuma and Serruys, {Patrick W.} and Beijk, {Marcel A. M.} and Koch, {Karel T.} and Jan Baan and Vis, {M. Marije} and Piek, {Jan J.} and Tijssen, {Jan G. P.} and Henriques, {Jose P. S.} and {de Winter}, {Robbert J.} and Wykrzykowska, {Joanna J.}",
year = "2019",
doi = "10.1002/ccd.28193",
language = "English",
journal = "Catheterization and Cardiovascular Interventions",
issn = "1522-1946",
publisher = "Wiley-Liss Inc.",

}

Tijssen, RYG, van der Schaaf, RJ, Kraak, RP, Vink, MA, Hofma, SH, Arkenbout, EK, Weevers, APJD, Kerkmeijer, LSM, Onuma, Y, Serruys, PW, Beijk, MAM, Koch, KT, Baan, J, Vis, MM, Piek, JJ, Tijssen, JGP, Henriques, JPS, de Winter, RJ & Wykrzykowska, JJ 2019, 'Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy' Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.28193

Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. / Tijssen, Ruben Y. G.; van der Schaaf, Rene J.; Kraak, Robin P.; Vink, Maarten A.; Hofma, Sjoerd H.; Arkenbout, E. Karin; Weevers, Auke P. J. D.; Kerkmeijer, Laura S. M.; Onuma, Yoshinobu; Serruys, Patrick W.; Beijk, Marcel A. M.; Koch, Karel T.; Baan, Jan; Vis, M. Marije; Piek, Jan J.; Tijssen, Jan G. P.; Henriques, Jose P. S.; de Winter, Robbert J.; Wykrzykowska, Joanna J.

In: Catheterization and Cardiovascular Interventions, 2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy

AU - Tijssen, Ruben Y. G.

AU - van der Schaaf, Rene J.

AU - Kraak, Robin P.

AU - Vink, Maarten A.

AU - Hofma, Sjoerd H.

AU - Arkenbout, E. Karin

AU - Weevers, Auke P. J. D.

AU - Kerkmeijer, Laura S. M.

AU - Onuma, Yoshinobu

AU - Serruys, Patrick W.

AU - Beijk, Marcel A. M.

AU - Koch, Karel T.

AU - Baan, Jan

AU - Vis, M. Marije

AU - Piek, Jan J.

AU - Tijssen, Jan G. P.

AU - Henriques, Jose P. S.

AU - de Winter, Robbert J.

AU - Wykrzykowska, Joanna J.

PY - 2019

Y1 - 2019

N2 - Background: Patients with acute coronary syndrome (ACS) might represent a specific subgroup, in which bioresorbable scaffold implantation in percutaneous coronary intervention (PCI), might lead to better outcomes when compared to conventional treatment with metallic drug eluting stents. In this prespecified subgroup analysis of the Amsterdam Investigator-Initiated Absorb Strategy All-Comers (AIDA) trial, we evaluated the clinical outcomes of Absorb bioresorbable vascular scaffold (BVS) versus Xience everolimus eluting stent (EES) treated patients presenting either with or without ACS. Methods and results: We classified AIDA patients on the basis of clinical presentation of ACS or of no-ACS. The rate of the 2-year primary endpoint of target vessel failure (TVF) was similar after treatment with Absorb BVS or Xience EES in ACS patients (10.2% versus 9.0% respectively; P = 0.49) and in no-ACS patients (11.7% versus 10.7%, respectively; P = 0.67) Definite or probable device thrombosis occurred more frequently with Absorb BVS compared to Xience EES in ACS patients (4.3% versus 1.7%, respectively, P = 0.03) as well as in no-ACS patients (2.4% versus 0.2%, respectively; P = 0.002). There were no statistically significant interactions between clinical presentation and randomized device modality for TVF (P = 0.80) and for the endpoint of definite or probable device thrombosis (P = 0.17). Conclusion: In the AIDA trial, the 2-year outcomes of PCI with Absorb BVS versus Xience EES were consistent in ACS and no-ACS patients: similar rates for TVF and consistently higher rates of definite or probable stent thrombosis under Absorb BVS versus Xience EES. There were no statistically significant interactions between clinical presentation and randomized device modality.

AB - Background: Patients with acute coronary syndrome (ACS) might represent a specific subgroup, in which bioresorbable scaffold implantation in percutaneous coronary intervention (PCI), might lead to better outcomes when compared to conventional treatment with metallic drug eluting stents. In this prespecified subgroup analysis of the Amsterdam Investigator-Initiated Absorb Strategy All-Comers (AIDA) trial, we evaluated the clinical outcomes of Absorb bioresorbable vascular scaffold (BVS) versus Xience everolimus eluting stent (EES) treated patients presenting either with or without ACS. Methods and results: We classified AIDA patients on the basis of clinical presentation of ACS or of no-ACS. The rate of the 2-year primary endpoint of target vessel failure (TVF) was similar after treatment with Absorb BVS or Xience EES in ACS patients (10.2% versus 9.0% respectively; P = 0.49) and in no-ACS patients (11.7% versus 10.7%, respectively; P = 0.67) Definite or probable device thrombosis occurred more frequently with Absorb BVS compared to Xience EES in ACS patients (4.3% versus 1.7%, respectively, P = 0.03) as well as in no-ACS patients (2.4% versus 0.2%, respectively; P = 0.002). There were no statistically significant interactions between clinical presentation and randomized device modality for TVF (P = 0.80) and for the endpoint of definite or probable device thrombosis (P = 0.17). Conclusion: In the AIDA trial, the 2-year outcomes of PCI with Absorb BVS versus Xience EES were consistent in ACS and no-ACS patients: similar rates for TVF and consistently higher rates of definite or probable stent thrombosis under Absorb BVS versus Xience EES. There were no statistically significant interactions between clinical presentation and randomized device modality.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85064178688&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30968559

U2 - 10.1002/ccd.28193

DO - 10.1002/ccd.28193

M3 - Article

JO - Catheterization and Cardiovascular Interventions

JF - Catheterization and Cardiovascular Interventions

SN - 1522-1946

ER -